Cover Image

Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events

Introduction: Despite recent advancements in the treatment of metastatic uveal melanoma (UM), the availability of further treatment options remains limited and the prognosis continues to be poor in many cases. In addition to tebentafusp, immune checkpoint blockade (ICB, PD-1 (+/-) CTLA-4 antibodies)...

Full description

Saved in:
Bibliographic Details
Main Authors: Koch, Elias A. T. (Author) , Petzold, Anne (Author) , Dippel, Edgar (Author) , Erdmann, Michael (Author) , Gesierich, Anja (Author) , Gutzmer, Ralf (Author) , Hassel, Jessica C. (Author) , Haferkamp, Sebastian (Author) , Kähler, Katharina C. (Author) , Kreuzberg, Nicole (Author) , Leiter, Ulrike (Author) , Loquai, Carmen (Author) , Meier, Friedegund (Author) , Meissner, Markus (Author) , Mohr, Peter (Author) , Pföhler, Claudia (Author) , Rahimi, Farnaz (Author) , Schell, Beatrice (Author) , Terheyden, Patrick (Author) , Thoms, Kai-Martin (Author) , Ugurel, Selma (Author) , Ulrich, Jens (Author) , Utikal, Jochen (Author) , Weichenthal, Michael (Author) , Ziller, Fabian (Author) , Berking, Carola (Author) , Heppt, Markus V. (Author)
Format: Article (Journal)
Language:English
Published: 10 June 2024
In: Frontiers in immunology
Year: 2024, Volume: 15, Pages: 1-11
ISSN:1664-3224
DOI:10.3389/fimmu.2024.1395225
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.3389/fimmu.2024.1395225
Verlag, kostenfrei, Volltext: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1395225/full
Get full text
Author Notes:Elias A. T. Koch, Anne Petzold, Edgar Dippel, Michael Erdmann, Anja Gesierich, Ralf Gutzmer, Jessica C. Hassel, Sebastian Haferkamp, Katharina C. Kähler, Nicole Kreuzberg, Ulrike Leiter, Carmen Loquai, Friedegund Meier, Markus Meissner, Peter Mohr, Claudia Pföhler, Farnaz Rahimi, Beatrice Schell, Patrick Terheyden, Kai-Martin Thoms, Selma Ugurel, Jens Ulrich, Jochen Utikal, Michael Weichenthal, Fabian Ziller, Carola Berking, Markus V. Heppt
Description
Summary:Introduction: Despite recent advancements in the treatment of metastatic uveal melanoma (UM), the availability of further treatment options remains limited and the prognosis continues to be poor in many cases. In addition to tebentafusp, immune checkpoint blockade (ICB, PD-1 (+/-) CTLA-4 antibodies) is commonly used for metastatic UM, in particular in HLA-A 02:01-negative patients. However, ICB comes at the cost of potentially severe immune-related adverse events (irAE). Thus, the selection of patient groups that are more likely to benefit from ICB is desirable. Methods: In this analysis, 194 patients with metastatic UM undergoing ICB were included. Patients were recruited from German skin cancer sites and the ADOReg registry. To investigate the association of irAE occurrence with treatment response, progression-free survival (PFS), and overall survival (OS) two cohorts were compared: patients without irAE or grade 1/2 irAE (n=137) and patients with grade 3/4 irAE (n=57). Results: In the entire population, the median OS was 16.4 months, and the median PFS was 2.8 months. Patients with grade 3/4 irAE showed more favorable survival than patients without or grade 1/2 irAE (p=0.0071). IrAE occurred in 44.7% (87/194), and severe irAE in 29.4% (57/194) of patients. Interestingly, irColitis and irHepatitis were significantly associated with longer OS (p=0.0031 and p=0.011, respectively). Conclusions: This data may indicate an association between irAE and favorable survival outcomes in patients with metastatic UM undergoing ICB treatment and suggests that a reduced tolerance to tumor antigens could be linked to reduced tolerance to self-antigens.
Item Description:Gesehen am 28.01.2025
Physical Description:Online Resource
ISSN:1664-3224
DOI:10.3389/fimmu.2024.1395225

Similar Items